169 related articles for article (PubMed ID: 36941804)
1. Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism.
O'Hara A; Pozin J; Darki A; Siddiqui F; Hoppensteadt D; Walenga J; Fareed J; Kantarcioglu B
Clin Appl Thromb Hemost; 2023; 29():10760296231165058. PubMed ID: 36941804
[TBL] [Abstract][Full Text] [Related]
2. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
Stubblefield WB; Alves NJ; Rondina MT; Kline JA
PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
Liu YF; Hou N; Shi YJ; Li CX; Gao YJ; Liu LN
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1638-1642. PubMed ID: 37248064
[No Abstract] [Full Text] [Related]
4. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Aso Y; Wakabayashi S; Yamamoto R; Matsutomo R; Takebayashi K; Inukai T
Diabetes Care; 2005 Sep; 28(9):2211-6. PubMed ID: 16123492
[TBL] [Abstract][Full Text] [Related]
5. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
6. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
7. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic Status and Risk of Death After Acute Pulmonary Embolism.
Brailovsky Y; Lakhter V; Newman J; Allen S; Elkaryoni A; Desai P; Masic D; Bechara CF; Bontekoe E; Hoppensteadt D; Lopez JJ; Siddiqui F; Iqbal O; Fareed J; Darki A
Clin Appl Thromb Hemost; 2023; 29():10760296231162079. PubMed ID: 36911974
[TBL] [Abstract][Full Text] [Related]
10. The Relevance of Thrombo-Inflammatory Biomarkers and Their Relationship with Circulating Glycosaminoglycans in End-Stage Renal Disease Patients.
Allen M; Bansal V; Siddiqui F; Hoppensteadt D; Krupa E; Fareed J; Kantarcioglu B
Clin Appl Thromb Hemost; 2023; 29():10760296231169512. PubMed ID: 37062946
[TBL] [Abstract][Full Text] [Related]
11. Tissue plasminogen activator plasma levels as a potential diagnostic aid in acute pulmonary embolism.
Flores J; García-Avello A; Flores VM; Navarro JL; Canseco F; Pérez-Rodríguez E
Arch Pathol Lab Med; 2003 Mar; 127(3):310-5. PubMed ID: 12653574
[TBL] [Abstract][Full Text] [Related]
12. Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism.
Kantarcioglu B; Darki A; Siddiqui F; Krupa E; Vural M; Kacmaz M; Hoppensteadt D; Iqbal O; Jeske W; Walenga J; Adiguzel C; Fareed J
Clin Appl Thromb Hemost; 2022; 28():10760296221104801. PubMed ID: 35733366
[TBL] [Abstract][Full Text] [Related]
13. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Antovic JP; Schulman S; An SS; Greenfield RS; Blombäck M
Scand J Clin Lab Invest; 2004; 64(8):745-51. PubMed ID: 15719893
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
15. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers.
Erdogan M; Solmaz S; Canataroglu A; Kulaksızoglu M; Cetinkalp S; Ozgen AG; Saygili F; Yilmaz C
Endocrine; 2010 Jun; 37(3):449-54. PubMed ID: 20960167
[TBL] [Abstract][Full Text] [Related]
16. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
17. Association of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism.
Yıldız A; Katar D; Soydaş AÖ; Albayrak M
Hamostaseologie; 2022 Jun; 42(3):180-184. PubMed ID: 34139773
[TBL] [Abstract][Full Text] [Related]
18. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
19. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
20. Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications.
Sherif EM; Elbarbary NS; Abd Al Aziz MM; Mohamed SF
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):451-7. PubMed ID: 24509335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
